Results 221 to 230 of about 5,331,742 (248)

Multidisciplinary Treatment for Esophagogastric Junction Cancer From a Dutch Perspective

Annals of Gastroenterological Surgery, Volume 10, Issue 5, Page 1404-1418, September 2026.
ABSTRACT Esophagogastric junction (EGJ) cancer is an increasing health burden worldwide. Over the past decade, significant advancements in centralization, multimodal treatment strategies, as well as the widespread adoption of minimally invasive surgical techniques, have led to marked improvements in perioperative outcomes and overall survival of EGJ ...
Hidde C. G. Overtoom, Suzanne S. Gisbertz   +1 more
wiley   +1 more source

ASO Author Reflections: Serum IgA as a Predictive Biomarker for Immunotherapy in Esophageal Squamous Cell Carcinoma. [PDF]

Ann Surg Oncol
Torii K, Iizuka A, Kanda M.
europepmc   +1 more source

POFUT1 Serves as an Independent Prognostic Factor and Therapeutic Target by Activating the PI3K/AKT Pathway in Glioma

Brain and Behavior, Volume 16, Issue 9, September 2026.
ABSTRACT Objective Protein O‐fucosyltransferase 1 (POFUT1) has been implicated in several malignancies, but its functional and prognostic significance in glioma remains insufficiently defined. This study evaluated whether POFUT1 expression is associated with glioma progression, patient outcome, and PI3K/AKT pathway activity.
Kai Yang, Chunlei Ju, Yifan Wang, Aijie Guo, Xiaochen Yang, Yang Mi, Yifei Su, Chunhong Wang, Hongming Ji   +8 more
wiley   +1 more source

Age and CIRS-G for risk stratification in elderly esophageal squamous cell carcinoma patients receiving definitive chemoradiotherapy. [PDF]

Front Oncol
Li M, Zhang B, Hao J, Song G, Zhang M, Hao Y, Zhao L, Wu Y, Lu F, Zhang Q.   +9 more
europepmc   +1 more source

Camrelizumab plus nimotuzumab as second-line therapy for advanced esophageal squamous cell carcinoma: a multicenter phase II study. [PDF]

J Immunother Cancer
Xia J, Meng X, Jiang G, Hong Y, Ji Y, Wang C, Yang X, Meng Y, Zhang W, Luo Z, Cui D, Wang J, Shan Z, Guan L, Lu Y, Yang X, Ren C, Meng X, Wang H, Shen L, Zhang Y, Kou Z, Lu T, Fan Q, Quante M, Zhao T, Li S, Wang F.   +27 more
europepmc   +1 more source

Single-cell-derived ferroptosis signature predicts prognosis and therapy response in esophageal squamous cell carcinoma. [PDF]

Front Oncol
Xu Q, Ma Y, Huang X, Abdukirim E, Yang M, Song C, Liu M.   +6 more
europepmc   +1 more source

[Retracted] Reduced expression levels of the death-associated protein kinase and E-cadherin are correlated with the development of esophageal squamous cell carcinoma. [PDF]

Exp Ther Med
Zhai J, Yang X, Zhang Y, Qi Q, Hu J, Wang Q.   +5 more
europepmc   +1 more source

Ethnic genomic diversity in esophageal squamous cell carcinoma. [PDF]

World J Gastrointest Oncol
Li WM, Jiao Y, Liu SQ, Wang CX, He M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

Cancer Cell, 2022
Yun Fan, Guanghai Dai, Junhe Li
exaly  

Overview of Risk Factors for Esophageal Squamous Cell Carcinoma in China

Cancers, 2023
Erica Conway, Haisheng Wu
exaly